Stem Cell Bioprocessing and Manufacturing, Volume 2

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Regenerative Engineering".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 8463

Special Issue Editors

Department of Bioengineering and iBB- Institute of Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa , Portugal
Interests: stem cells research for tissue engineering and regenerative medicine; stem cell bioprocessing and manufacturing: development of novel stem cell bioreactors and advanced bioseparation and purification processes
Special Issues, Collections and Topics in MDPI journals
Department of Bioengineering and IBB - Institute of Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal
Interests: bone marrow niche; expansion of human stem cells; cellular therapies with stem cells; bioreactors for stem cell culture and production of extracellular vesicles
Special Issues, Collections and Topics in MDPI journals
Department of Bioengineering and iBB - Institute of Bioengineering and Biosciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal
Interests: the development of scalable platforms for highly controlled expansion and differentiation of human pluripotent stem cells (hPSC), embryonic (hESC), induced pluripotent stem cells (hiPSC); stem cell-based purification strategies; regenerative medicine; drug screening; disease modelling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The next healthcare revolution will apply regenerative medicines using human cells and tissues. The aim of the regenerative medicine approach is to create biological therapies or substitutes in vitro for the replacement or restoration of tissue function in vivo lost through failure or disease. However, whilst science has revealed the potential, and early products have shown the power of such therapies, there is an immediate and long-term need for expertise with the necessary skills to face the engineering and life science challenges before the predicted benefits in human healthcare can be realized. Specifically, there is a need for the development of bioprocess technology for the successful transfer of laboratory-based practice of stem cell and tissue culture to the clinic as therapeutics through the application of engineering principles and practices. This Special Issue of Bioengineering on “Stem Cell Bioprocessing and Manufacturing, Volume 2” addresses the central role in defining the engineering sciences of cell-based therapies by bringing together contributions from worldwide experts on stem cell biology and engineering, bioreactor design and bioprocess development, scale-up, and manufacturing of stem cell-based therapies.

You can see the previous project here: https://www.mdpi.com/journal/bioengineering/special_issues/stem_cell_bioprocess (Volume 1).

Prof. Dr. Joaquim M. S. Cabral
Assoc. Prof. Dr. Cláudia Lobato da Silva 
Assist. Prof. Dr. Maria Margarida Diogo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 7587 KiB  
Communication
Cell Culture Process Scale-Up Challenges for Commercial-Scale Manufacturing of Allogeneic Pluripotent Stem Cell Products
by Brian Lee, Sunghoon Jung, Yas Hashimura, Maximilian Lee, Breanna S. Borys, Tiffany Dang, Michael S. Kallos, Carlos A. V. Rodrigues, Teresa P. Silva and Joaquim M. S. Cabral
Bioengineering 2022, 9(3), 92; https://doi.org/10.3390/bioengineering9030092 - 25 Feb 2022
Cited by 9 | Viewed by 4804
Abstract
Allogeneic cell therapy products, such as therapeutic cells derived from pluripotent stem cells (PSCs), have amazing potential to treat a wide variety of diseases and vast numbers of patients globally. However, there are various challenges related to manufacturing PSCs in single-use bioreactors, particularly [...] Read more.
Allogeneic cell therapy products, such as therapeutic cells derived from pluripotent stem cells (PSCs), have amazing potential to treat a wide variety of diseases and vast numbers of patients globally. However, there are various challenges related to manufacturing PSCs in single-use bioreactors, particularly at larger volumetric scales. This manuscript addresses these challenges and presents potential solutions to alleviate the anticipated bottlenecks for commercial-scale manufacturing of high-quality therapeutic cells derived from PSCs. Full article
(This article belongs to the Special Issue Stem Cell Bioprocessing and Manufacturing, Volume 2)
Show Figures

Figure 1

15 pages, 3973 KiB  
Article
Effective Label-Free Sorting of Multipotent Mesenchymal Stem Cells from Clinical Bone Marrow Samples
by Silvia Zia, Carola Cavallo, Ilaria Vigliotta, Valentina Parisi, Brunella Grigolo, Roberto Buda, Pasquale Marrazzo, Francesco Alviano, Laura Bonsi, Andrea Zattoni, Pierluigi Reschiglian and Barbara Roda
Bioengineering 2022, 9(2), 49; https://doi.org/10.3390/bioengineering9020049 - 22 Jan 2022
Cited by 7 | Viewed by 3102
Abstract
Mesenchymal stem cells (MSC) make up less than 1% of the bone marrow (BM). Several methods are used for their isolation such as gradient separation or centrifugation, but these methodologies are not direct and, thus, plastic adherence outgrowth or magnetic/fluorescent-activated sorting is required. [...] Read more.
Mesenchymal stem cells (MSC) make up less than 1% of the bone marrow (BM). Several methods are used for their isolation such as gradient separation or centrifugation, but these methodologies are not direct and, thus, plastic adherence outgrowth or magnetic/fluorescent-activated sorting is required. To overcome this limitation, we investigated the use of a new separative technology to isolate MSCs from BM; it label-free separates cells based solely on their physical characteristics, preserving their native physical properties, and allows real-time visualization of cells. BM obtained from patients operated for osteochondral defects was directly concentrated in the operatory room and then analyzed using the new technology. Based on cell live-imaging and the sample profile, it was possible to highlight three fractions (F1, F2, F3), and the collected cells were evaluated in terms of their morphology, phenotype, CFU-F, and differentiation potential. Multipotent MSCs were found in F1: higher CFU-F activity and differentiation potential towards mesenchymal lineages compared to the other fractions. In addition, the technology depletes dead cells, removing unwanted red blood cells and non-progenitor stromal cells from the biological sample. This new technology provides an effective method to separate MSCs from fresh BM, maintaining their native characteristics and avoiding cell manipulation. This allows selective cell identification with a potential impact on regenerative medicine approaches in the orthopedic field and clinical applications. Full article
(This article belongs to the Special Issue Stem Cell Bioprocessing and Manufacturing, Volume 2)
Show Figures

Figure 1

Back to TopTop